Clinical Trial Detail

NCT ID NCT02873975
Title A Study of LY2606368 (Prexasertib) in Patients With Solid Tumors With Replicative Stress or Homologous Repair Deficiency
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Dana-Farber Cancer Institute
Indications

Advanced Solid Tumor

Therapies

Prexasertib

Age Groups: adult senior

Additional content available in CKB BOOST